This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Output Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
results for ""
Sort
Filter & Sort
-
Output Type
-
Program
-
CRN Team Name
-
Theme
Nigrostriatal Tau Pathology in parkinsonism and Parkinson’s disease
While Parkinson’s disease remains clinically defined by cardinal motor symptoms resulting from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of multiple pathologies, but it is unclear where these…
Calf intestine alkaline phosphatase (CIAP) treatment
Protocol selectively dephosphorylates non-aggregated PSER129, improving detection of aggregated PSER129, aiding in distinguishing between physiological and disease-related forms of alpha-synuclein.
Rotarod
Rotarod protocol optimized for mice. This test is made to assess motor coordination and balance. The results should show lower latency to fall numbers for mice with motor impairments.
Purification of Proteins from PFA Fixed Samples
Protocol for purifying proteins from PFA-fixed samples and extracting proteins from formalin-fixed tissues, including biotin pulldown before LC-MS/MS. Samples used for mass spectrometry, immunoblotting, and pulldowns.
Multiplex Labeling with Tyramide Fluorophores (Free-Floating Tissues)-Killinger Lab 2024
Protocol for multiplex labeling of free-floating tissues with tyramide fluorophores in the Killinger lab (2024).
Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy
Parkinson’s disease (PD) involves motor symptoms and αsyn aggregation. GBA1 mutations may worsen PD progression. Testing showed similar αsyn spread regardless of genotype or αsyn strain, with unique interactions found in GBA-PD brains.
Alpha-synuclein aggregates are phosphatase resistant
CIAP pretreatment has important implications for the mechanism of PSER129-accumulation in the synucleinopathy brain and provides a simple experimental method to differentiate endogenous from aggregated PSER129.
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease
Study focuses on mild motor deficits not meeting Parkinson's criteria. Nigrostriatal system changes occur regardless of alpha-synuclein presence, hinting at tau-mediated dopaminergic neurodegeneration initiation. Tau pathology seen in affected groups